Nivolumab: beside a new treatment under test
581 studies: a new drug, cell therapy or vaccine is what the study tests. Page 2 of 6. Open to participants first (106), then studies with results posted, then the rest; newest registration first within each.
- DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular CarcinomaRecruitingNCT04248569Phase 1How we knowReport a problem
- INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory MalignanciesRecruitingNCT03838042Phase 1/2How we knowReport a problem
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsRecruitingNCT03686124Phase 1/2How we knowReport a problem
- Combination of TATE and PD-1 Inhibitor in Liver CancerRecruitingNCT03259867Phase 2How we knowReport a problem
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 1How we knowReport a problem
- Phase I Trial: T4 Immunotherapy of Head and Neck CancerRecruitingNCT01818323Phase 1How we knowReport a problem
- A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)TerminatedNCT06094296Phase 2Results postedHow we knowReport a problem
- Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor MalignanciesTerminatedNCT05846659Phase 2Results postedHow we knowReport a problem
- Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCCTerminatedNCT05846646Phase 2Results postedHow we knowReport a problem
- EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian CancerActive, not recruitingNCT05715216Phase 2Results postedHow we knowReport a problem
- EO4010 in Previously Treated Metastatic Colorectal CarcinomaTerminatedNCT05589597Phase 1/2Results postedHow we knowReport a problem
- A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung CancerTerminatedNCT05543629Phase 1/2Results postedHow we knowReport a problem
- A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid TumorsCompletedNCT05407675Phase 1/2Results postedHow we knowReport a problem
- EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal CancerTerminatedNCT05350501Phase 2Results postedHow we knowReport a problem
- A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate CancerTerminatedNCT05169684Phase 2Results postedHow we knowReport a problem
- Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)CompletedNCT05061017Phase 2Results postedHow we knowReport a problem
- A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerCompletedNCT05005273Phase 2Results postedHow we knowReport a problem
- A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaTerminatedNCT05002569Phase 3Results postedHow we knowReport a problem
- A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)CompletedNCT04907539Phase 2Results postedHow we knowReport a problem
- Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesTerminatedNCT04902040Phase 1/2Results postedHow we knowReport a problem
- Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain MetsTerminatedNCT04899921Phase 2Results postedHow we knowReport a problem
- Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)CompletedNCT04891770Phase 2Results postedHow we knowReport a problem
- Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyCompletedNCT04887870Phase 2/3Results postedHow we knowReport a problem
- First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBVCompletedNCT04778904Phase 1/2Results postedHow we knowReport a problem
- A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic TumorsCompletedNCT04761198Phase 1/2Results postedHow we knowReport a problem
- A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant CancerTerminatedNCT04730349Phase 1/2Results postedHow we knowReport a problem
- A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerCompletedNCT04702880Phase 2Results postedHow we knowReport a problem
- CMP-001 in Combination With Nivolumab in Subjects With Advanced MelanomaTerminatedNCT04698187Phase 2Results postedHow we knowReport a problem
- CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced MelanomaTerminatedNCT04695977Phase 2/3Results postedHow we knowReport a problem
- A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)CompletedNCT04623775Phase 2Results postedHow we knowReport a problem
- T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerTerminatedNCT04611126Phase 1/2Results postedHow we knowReport a problem
- Nivolumab Plus Relatlimab in Patients With Metastatic Uveal MelanomaCompletedNCT04552223Phase 2Results postedHow we knowReport a problem
- Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma PatientsCompletedNCT04526730Phase 2Results postedHow we knowReport a problem
- Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for RecurrenceTerminatedNCT04410445Phase 3Results postedHow we knowReport a problem
- UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of MelanomaCompletedNCT04382664Phase 2Results postedHow we knowReport a problem
- A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced CancersCompletedNCT04350463Phase 2Results postedHow we knowReport a problem
- Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsCompletedNCT04349267Phase 1/2Results postedHow we knowReport a problem
- Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast CancerTerminatedNCT04331067Phase 1/2Results postedHow we knowReport a problem
- Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid TumorsTerminatedNCT04319224Phase 1/2Results postedHow we knowReport a problem
- Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic CancerCompletedNCT04208958Phase 1/2Results postedHow we knowReport a problem
- A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/ParagangliomaTerminatedNCT04187404Phase 1/2Results postedHow we knowReport a problem
- VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)TerminatedNCT04166383Phase 2Results postedHow we knowReport a problem
- ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerTerminatedNCT04159896Phase 2Results postedHow we knowReport a problem
- Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143CompletedNCT04122625Phase 1/2Results postedHow we knowReport a problem
- First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive GlioblastomaCompletedNCT04116658Phase 1/2Results postedHow we knowReport a problem
- Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)TerminatedNCT04057365Phase 2Results postedHow we knowReport a problem
- Nivolumab Combined With BMS-986253 in HCC PatientsTerminatedNCT04050462Phase 2Results postedHow we knowReport a problem
- BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver CancersCompletedNCT04021043Phase 1/2Results postedHow we knowReport a problem
- ATL001 in Patients With Metastatic or Recurrent MelanomaTerminatedNCT03997474Phase 1/2Results postedHow we knowReport a problem
- An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid CancersCompletedNCT03994601Phase 1/2Results postedHow we knowReport a problem
- IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for MelanomaTerminatedNCT03958383Phase 1/2Results postedHow we knowReport a problem
- Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaActive, not recruitingNCT03929029Phase 1Results postedHow we knowReport a problem
- Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell LymphomaCompletedNCT03927105Phase 2Results postedHow we knowReport a problem
- Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerTerminatedNCT03906071Phase 3Results postedHow we knowReport a problem
- ABX196 in Combination With Nivolumab in Patients With Hepatocellular CarcinomaCompletedNCT03897543Phase 1/2Results postedHow we knowReport a problem
- Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel CombinationsCompletedNCT03835533Phase 1Results postedHow we knowReport a problem
- Avadomide (CC-122) in Combination With Nivolumab in Advanced MelanomaCompletedNCT03834623Phase 2Results postedHow we knowReport a problem
- Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome InterventionCompletedNCT03817125Phase 1Results postedHow we knowReport a problem
- VAccination in Early and ADvanced Prostate caNCErTerminatedNCT03815942Phase 1/2Results postedHow we knowReport a problem
- A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid TumorsCompletedNCT03792750Phase 1/2Results postedHow we knowReport a problem
- BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRCTerminatedNCT03791398Phase 1/2Results postedHow we knowReport a problem
- A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial CancerCompletedNCT03785925Phase 2Results postedHow we knowReport a problem
- Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple MyelomaTerminatedNCT03782064Phase 2Results postedHow we knowReport a problem
- Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.CompletedNCT03767582Phase 1/2Results postedHow we knowReport a problem
- A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)TerminatedNCT03729245Phase 3Results postedHow we knowReport a problem
- Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II ExpressionTerminatedNCT03724968Phase 2Results postedHow we knowReport a problem
- A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced MelanomaCompletedNCT03711188Phase 2Results postedHow we knowReport a problem
- Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic CancerCompletedNCT03697564Phase 2Results postedHow we knowReport a problem
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver CancerTerminatedNCT03695250Phase 1/2Results postedHow we knowReport a problem
- A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 MutationCompletedNCT03684811Phase 1/2Results postedHow we knowReport a problem
- Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell CarcinomaCompletedNCT03680521Phase 2Results postedHow we knowReport a problem
- Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal CancerCompletedNCT03642067Phase 2Results postedHow we knowReport a problem
- A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102CompletedNCT03636477Phase 1Results postedHow we knowReport a problem
- A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaCompletedNCT03635983Phase 3Results postedHow we knowReport a problem
- CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node DiseaseCompletedNCT03618641Phase 2Results postedHow we knowReport a problem
- A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaTerminatedNCT03606174Phase 2Results postedHow we knowReport a problem
- pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate CancerActive, not recruitingNCT03600350Phase 2Results postedHow we knowReport a problem
- Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic CancerTerminatedNCT03599362Phase 2Results postedHow we knowReport a problem
- Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic TumorsCompletedNCT03583086Phase 1/2Results postedHow we knowReport a problem
- A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung CancerCompletedNCT03575793Phase 1/2Results postedHow we knowReport a problem
- Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell CarcinomaTerminatedNCT03562507Phase 2Results postedHow we knowReport a problem
- Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell CarcinomaTerminatedNCT03552380Phase 2Results postedHow we knowReport a problem
- A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRCTerminatedNCT03547999Phase 2Results postedHow we knowReport a problem
- Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerCompletedNCT03523572Phase 1Results postedHow we knowReport a problem
- APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell CarcinomaCompletedNCT03502330Phase 1Results postedHow we knowReport a problem
- BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)CompletedNCT03496662Phase 1/2Results postedHow we knowReport a problem
- Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeCompletedNCT03493932Phase 1Results postedHow we knowReport a problem
- A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaActive, not recruitingNCT03470922Phase 2/3Results postedHow we knowReport a problem
- An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedNCT03459222Phase 1/2Results postedHow we knowReport a problem
- Study to Evaluate the Safety and Tolerability of RXC004 in Advanced MalignanciesCompletedNCT03447470Phase 1Results postedHow we knowReport a problem
- An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have SpreadTerminatedNCT03446040Phase 1/2Results postedHow we knowReport a problem
- REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesTerminatedNCT03435640Phase 1/2Results postedHow we knowReport a problem
- A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersCompletedNCT03400332Phase 1/2Results postedHow we knowReport a problem
- Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory CancersCompletedNCT03388632Phase 1Results postedHow we knowReport a problem
- Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung CancerTerminatedNCT03382912Phase 2Results postedHow we knowReport a problem
- An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the LungTerminatedNCT03371381Phase 1/2Results postedHow we knowReport a problem
- A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsCompletedNCT03369223Phase 1/2Results postedHow we knowReport a problem
- An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial CancersTerminatedNCT03363776Phase 1/2Results postedHow we knowReport a problem
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT03358719Phase 1Results postedHow we knowReport a problem
- A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03353675Phase 2Results postedHow we knowReport a problem